Everything You Need to Know About the OIG Special Fraud Alert

The OIG’s Special Fraud Alert raised concerns towards some characteristics of speaker programs that may be considered risky. These programs, however, are necessary to educate healthcare professionals (HCPs) through Peer-to-Peer (P2P) educational strategies. When conducting P2P speaker programs, you can avoid some of the risks flagged by the OIG, and ensure that you are able to conduct successful educational programs. This page contains various resources to help you address your P2P marketing strategies going forward.

OIG Comparison
ARTICLE: How to Manage the Post-COVID-19 World of Speaker Programs after OIG’s New Special Fraud Alert

The COVID-19 pandemic has shown us how important the execution of successful virtual environments can be. In addition to being less expensive and more customized for HCPs, Virtual Speaker Programs also reduce the risks that were recently flagged by the OIG’s Special Fraud Alert. This blog post explains how to ensure that biopharma marketers are delivering educational information that adheres to the OIG’s guidelines.

VIDEO: Limiting Speaker Program Risks in Light of The OIG’s Special Fraud Alert

Speaker Programs provide tremendous value because they allow HCPs to learn important information to improve patient care through the collective experience of experts and colleagues in their fields. We did an internal analysis to determine how applicable the OIG’s guidance can be to Peer-to-Peer Speaker Programs, determining alternatives to modify programs and reduce risk. In this short video, V2V President Dan Rehal discusses the key factors to consider when conducting Speaker Programs and gets you up to speed in under 13 minutes.

ON-DEMAND WEBINAR: What to Do Now After OIG’s Special Fraud Alert 

Considering the concerns expressed in the OIG’s Special Fraud Alert, it is important to understand how to conduct speaker programs without increasing compliance risk. Watch V2V President Dan Rehal and biopharma industry experts Brian Dahl (Dahl Compliance Consulting) and Gary Mendelsohn (Astellas Pharma, U.S) as they dive into the future of speaker programs following the OIG’s guidance in this roundtable discussion. They discuss the impact of the alert on Speaker Bureaus, KOLs, HCPs and Healthcare Marketers, what can be done to limit an organization’s risk, and answer audience questions during a live Q&A session to provide actionable insights for P2P programs. WATCH NOW

ABOUT THE AUTHOR

Picture of Daniel J. Rehal

Daniel J. Rehal

As President of Vision2Voice, Daniel thoroughly understands the pharmaceutical industry from the ground floor up. By ascending the ranks at Merck to his global responsibilities at Takeda, Dan has significant experience in both marketing and sales roles supporting a multitude of pharmaceutical brands as an award-winning Sales Representative, Training Manager, District Manager, Senior Product Manager, and Marketing Director.

Recent Posts

Globe with Pills

BioPharma in the News – April 2026

The FDA is escalating its ongoing push for transparency and tougher enforcement, including publicizing complete response letters, seeking new authority over DTC drug advertising, and...

Read More
Speaker Standing Next to Broken Clock

When the Universe Has Other Plans: How to Save a Speaker Program in Crisis

It’s the perfect storm: TSA staffing shortages, extreme weather, constant flight delays, and airlines cutting hundreds of flights daily1. There is an in-person speaker program...

Read More
Speakers on a Shelf

Your Speaker’s Bureau Has a Shelf Life: Here’s How to Know When It Needs a Refresh

Nobody wants to be the last one to realize the shelf life of their milk has expired. Yet in biopharma marketing, it happens with speaker’s...

Read More